In glioblastoma cells, the use of olaptesed pegol as a combination therapy has been reported to be effective in reducing the recruitment of tumor-associated macrophages due to CXCL12 increase after anti-VEGF therapy 46. This evidence concerns the gene VEGFA and glioblastoma.